Holen Sie sich die Stockscreener-App
3.485
2.65%
-0.095
Schlusskurs vom Vortag:
$3.58
Offen:
$3.55
24-Stunden-Volumen:
338.52K
Relative Volume:
1.37
Marktkapitalisierung:
$128.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-12.66%
1M Leistung:
-24.73%
6M Leistung:
-82.34%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.47
$3.58
1-Wochen-Bereich:
$3.47
$4.04
52-Wochen-Spanne:
$3.47
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
1445A SOUTH 50TH STREET, RICHMOND
Vergleichen Sie BIOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
3.485 | 128.34M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.32 | 17.38B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.87 | 14.05B | 612.78M | -86.37M | -62.91M | -0.87 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
Several Insiders Invested In BioAge Labs Flagging Positive News - Yahoo Finance
Cautious Outlook on BioAge Labs Amid Promising Developments and High Risk - TipRanks
BioAge Labs, Inc.: Sell Rating Due to Discontinued Program and Uncertain Prospects - TipRanks
BioAge Labs Inc. (BIOA) reports earnings - Quartz
BioAge Labs, Inc. Advances NLRP3 Inhibitor BGE-102 and Forms Strategic Collaborations with Novartis and Lilly for Metabolic Diseases - Nasdaq
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the - Bluefield Daily Telegraph
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 - TradingView
BioAge Labs Lands Massive $550M Novartis Deal Despite Clinical Setback in 2024 Results - Stock Titan
Final Deadline for the BioAge Labs, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsBIOA - The Malaysian Reserve
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit - PR Newswire
BIOA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors - Bluefield Daily Telegraph
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Bioage Labs principal accounting officer Barton Shane buys $47,376 in common stock By Investing.com - Investing.com South Africa
Bioage Labs principal accounting officer Barton Shane buys $47,376 in common stock - Investing.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs - Markets Insider
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi ... - Bluefield Daily Telegraph
2025-03-10 | Shareholders that Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing
DEADLINE ALERT for REGN and BIOA: The Law Offices of Frank - GlobeNewswire
BIOA FINAL DEADLINE: BioAge Labs Investors are Encouraged - GlobeNewswire
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm - themalaysianreserve.com
Investors in BioAge Labs, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your RightsBIOA - GuruFocus.com
BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025BIOA - PR Newswire
2025-03-09 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. LawsuitBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing
Class Action Filed Against BioAge Labs, Inc. (BIOA)March 10, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
BioAge Labs, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsBIOA - ACCESS Newswire
BIOA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. (BIOA) Investors of Filing Deadline in Class Action Lawsuit | StreetInsider.com - Financial Content
BIOA LEGAL NEWS: A Class Action was filed on behalf of BioAge Labs Investors - GlobeNewswire Inc.
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman - GlobeNewswire
Faruqi & Faruqi Reminds BioAge Investors of the Pending Class Act - The National Law Review
BIOA Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge ... - Bluefield Daily Telegraph
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc. (BIOA) Shareholders - GlobeNewswire
BIOA DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors ... - The Bakersfield Californian
Deadline Soon: BioAge Labs, Inc. (BIOA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
BIOA Deadline: Rosen Law Firm Urges BioAge Labs, Inc. (NASDAQ: BIOA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Joplin Globe
Cautious Outlook on BioAge Labs, Inc. Amid Program Discontinuation and Development Risks - TipRanks
Faruqi & Faruqi Reminds BioAge Investors of the Pending - GlobeNewswire
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
The Gross Law Firm Notifies Shareholders of BioAge Labs, - GlobeNewswire
BIOA Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. (BIOA) Investors of Filing Deadline in Class Action Lawsuit - PR Newswire
INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Subst - GuruFocus.com
INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitBIOA - PR Newswire
BioAge Labs, Inc. (BIOA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
2025-03-06 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. LawsuitBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
BioAge Labs, Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
BioAge Labs, Inc. (NASDAQ: BIOA) Investor Notice: Deadline in Lawsuit on March 10, 2025 - openPR
Deadline Alert: BioAge Labs, Inc. (BIOA) Investors Who Lost - GlobeNewswire
BioAge Labs, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March - The Bakersfield Californian
BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit - The Malaysian Reserve
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioage Labs Inc-Aktie (BIOA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pande Vijay Satyanand | Director |
Oct 01 '24 |
Buy |
19.73 |
126,793 |
2,501,626 |
1,026,793 |
| Pande Vijay Satyanand | Director |
Oct 02 '24 |
Buy |
19.73 |
67,096 |
1,323,804 |
1,093,889 |
| Pande Vijay Satyanand | Director |
Oct 03 '24 |
Buy |
19.90 |
25,306 |
503,589 |
1,119,195 |
| Cormorant Asset Management, LP | Former 10% Owner |
Sep 27 '24 |
Buy |
18.00 |
450,000 |
8,100,000 |
1,629,529 |
| Pande Vijay Satyanand | Director |
Sep 27 '24 |
Buy |
18.00 |
900,000 |
16,200,000 |
900,000 |
| ENRIGHT PATRICK G | Director |
Sep 27 '24 |
Buy |
18.00 |
400,000 |
7,200,000 |
1,710,589 |
| HEALY JAMES | Director |
Sep 27 '24 |
Buy |
18.00 |
666,665 |
11,999,970 |
2,227,124 |
0.09%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):